Table 4.
Comparison of EORTC QLQ-C30, RCSQ, and Actiwatch results between patients with long and short overall survival (OS) after completion of FOLFIRINOX
| Patients with OS > 12 months (n = 11), mean score (SD) | Patients with OS < 12 months (n = 11), mean score (SD) | P | |
|---|---|---|---|
| Global health status (QoL) | 80.4 (13.9) | 76.5 (21.5) | 0.619 |
| Physical functioning | 81.2 (15.4) | 85.0 (11.1) | 0.520 |
| Role functioning | 71.2 (30.8) | 72.6 (34.4) | 0.918 |
| Emotional functioning | 82.6 (15.1) | 90.8 (13.3) | 0.193 |
| Cognitive functioning | 80.3 (91.7) | 91.7 (14.1) | 0.161 |
| Social functioning | 63.6 (33.1) | 80.5 (26.5) | 0.204 |
| Fatigue | 45.4 (22.7) | 24.1 (17.8) | 0.024 |
| Nausea and vomiting | 4.6 (10.7) | 0.0 (0.0) | 0.175 |
| Pain | 15.3 (23.0) | 21.2 (33.4) | 0.634 |
| Dyspnea | 24.2 (33.7) | 21.2 (34.3) | 0.838 |
| Insomnia | 30.2 (31.5) | 9.1 (21.6) | 0.082 |
| Appetite loss | 24.2 (33.7) | 9.0 (15.4) | 0.189 |
| Constipation | 12.1 (30.8) | 6.0 (13.4) | 0.554 |
| Diarrhea | 15.1 (22.9) | 12.0 (16.7) | 0.721 |
| Financial difficulties | 12.1 (30.8) | 6.0 (13.4) | 0.554 |
| Pain score NRS > 0, yes (%) | 3 (27.3) | 3 (27.3) | 1.000 |
| Sleep duration, hours | 8.6 (0.9) | 7.8 (1.4) | 0.142 |
| Sleep efficiency (%) | 76.1 (5.0) | 68.3 (9.8) | 0.039 |
| Sleep quality (RCSQ) | 72.4 (15.2) | 74.0 (10.7) | 0.783 |
P-values in bold are statistically significant
EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, QoL quality of life, RCSQ Richards-Campbell Sleep Questionnaire, SD standard deviation